EANS-News: DEWB Investment Holding NOXXON Announces the Completion of the First-in-Human Clinical Trial with Spiegelmer® NOX-A12

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

Berlin, Germany, May 03, 2010 (euro adhoc) - NOXXON Pharma AG, the
biopharmaceutical company focusing on the development of novel drugs
based on its unique proprietary Spiegelmer® technology, announced
today the successful completion of the first-in-human clinical trial
with Spiegelmer® NOX-A12.

This Phase I study was designed to evaluate the safety, tolerability,
pharmacokinetics, and pharmacodynamics in healthy individuals
following intravenous administration of the stromal cell-derived
factor-1 (SDF-1) antagonizing Spiegelmer® NOX-A12. Final data
analysis demonstrated an excellent safety and tolerability up to the
highest tested dose of 10.8 mg/kg. In addition, analysis by flow
cytometry revealed a long lasting and dose dependent mobilization of
WBC and CD34 positive cells. The protocol also allowed that an
additional group of volunteers would be dosed and be receiving a
leukapheresis procedure if certain thresholds of circulating CD34
positive cells were reached, to further characterize the mobilized
cells. This study goal was achieved, too. Further information about
the clinical trial is available on www.clinicaltrials.gov (ID:
NCT00976378).

Dr. Frank Morich, Chief Executive Officer of NOXXON, commented:
"Based on exceptionally positive pre-clinical and clinical data, we
strongly believe that NOX-A12 has the potential to be developed for
acute as well as chronic indications in the area of hematological
malignancies and/or solid tumors. NOX-A12 is scheduled to enter a
multiple dose Phase I clinical trial by mid of 2010, and phase II
clinical testing soon thereafter."

About NOX-A12 NOX-A12 specifically antagonizes stromal cell-derived
factor-1 (SDF-1), a chemokine which attracts and activates immune-
and non-immune cells. SDF-1 binds with high affinity to the chemokine
receptors CXCR4 and CXCR7. The CXCR4/SDF-1 axis has been shown to
play a role in stem cell mobilization, vasculogenesis, tumor growth
and metastasis. Inhibition of the SDF-1 binding to CXCR4 sensitizes
tumor cells to chemotherapy suggesting that NOX A12 in combination
with chemotherapy could be beneficial in the treatment of various
cancers.

NOX-A12 has been evaluated in models of stem cell mobilization,
angiogenesis, inflammation and lung and kidney injury. In these
models NOX-A12 reduced pathological angiogenesis and tissue
remodeling. In preclinical safety and two weeks toxicology studies
NOX-A12 was safe and did not show any organ toxicity. In particular
NOX-A12 did not exert any immunotoxicity effects, such as Toll-like
receptor activation or changes in cytokine levels.

NOXXON receives grant support (Grant no. 0315118) within the program
"KMU-innovativ" from the German Federal Ministry of Education and
Research (BMBF) for the preclinical program and the first-in-human
clinical trial with NOX-A12.

About Spiegelmers® Spiegelmers® (L-aptamers) are chemical entities
based on synthetic mirror-image oligonucleotides which are highly
selective for their pharmacological target and potent inhibitors of
target function. They combine the benefits of small molecule drugs
and biopharmaceuticals. Due to their unique mirror image
configuration Spiegelmers® are not metabolized and do not hybridize
with native nucleic acids. Unlike conventional nucleic acids,
Spiegelmers® do not activate the innate immune response via toll-like
receptors and they showed an exceptionally favorable immunogenicity
profile in pre-clinical testing.

About NOXXON Berlin-based NOXXON Pharma AG is a clinical stage
biotechnology company focusing on the development of Spiegelmers® for
the treatment of inflammatory diseases and hematological indications.
NOXXON is in possession of a broad patent estate and has access to a
readily scalable GMP production. In addition to its in-house
programs, NOXXON discovers and develops Spiegelmers® in collaboration
with partners from the pharmaceutical industry, including Eli Lilly
and Hoffmann La-Roche. The business strategy of NOXXON is to broaden
this range of collaborations through co-development and licensing
agreements for the proprietary clinical and pre-clinical products as
well as technology-based multi-target partnerships. Currently the
company has two compounds in clinical development. The declared goal
of NOXXON is to establish its oligonucleotide-based drug discovery
platform (Spiegelmers®) as the leading 'scaffold' technology to
create new chemical entities with superior properties.

NOXXON´s investors are TVM Capital, Sofinnova Partners, Edmond de
Rothschild Investment Partners, Deutsche Effecten- und
Wechsel-Beteiligungsgesellschaft (DEWB), Seventure Partners, Dow
Venture Capital, Dieckell Group, FCP OP MEDICAL BioHealth- Trends,
IBG Risikokapitalfonds, VC Fonds Berlin, and others.

Webseite: http://www.noxxon.com

General contact:
Emmanuelle Delabre
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany

Phone: + 49-30-726247-100
FAX: + 49-30-726247-225
Email: edelabre@noxxon.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Deutsche Effecten- und Wechsel-Beteiligungsges. AG (DEWB)
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Marco Scheidler

Tel.: +49 (0) 3641 573-3600

E-Mail: marco.scheidler@dewb-vc.com

Branche: Financial & Business Services
ISIN: DE0008041005
WKN: 804100
Index: CDAX, Classic All Share
Börsen: Berlin / free trade
Stuttgart / free trade
München / free trade
Frankfurt / regulated dealing/general standard